Trinidad Martín Campos, PhD

Dr. Trinidad Martín Campos conducts analysis support for Labcorp’s Genomics department, driving data analysis and pipeline development for a wide variety of assays, from qPCR- and array-based platforms to a full spectrum of next-generation sequencing assays. She is also the bioinformatician contact for PGDx in Europe, a complete test that enables rapid and actionable genomic insight for patients with advanced cancer.

Anthony Guihur, PhD

Dr. Anthony Guihur brings extensive experience in molecular biology, biochemistry, and “omics” (genomics, transcriptomics, proteomics) with a touch of bioinformatics and data analysis. He earned his PhD from the University of Tours in France where he specialized in plant secondary metabolism (terpene biosynthesis). He then held a postdoctoral position at the University of Lausanne in Switzerland, studying heat shock proteins in plants and other organisms.

Cell and Gene Therapy Answers: The critical role of flow cytometry in adoptive cell therapies

Adoptive cell therapy (ACT) is a promising type of immunotherapy that involves engineering a patient's immune cells to recognize and attack their cancer. As this field continues to grow, researchers are focused on refining the process to make ACT more effective in supporting the patient immune response. One critical tool for developing better ACT treatments is flow cytometry. To learn more about how flow cytometry enables advances in ACTs, we spoke with Leanne Flye, associate director of scientific operations, general laboratory, at Labcorp.

Cell and Gene Therapy Answers: The critical role of flow cytometry in adoptive cell therapies

Adoptive cell therapy (ACT) is a promising type of immunotherapy that involves engineering a patient's immune cells to recognize and attack their cancer. As this field continues to grow, researchers are focused on refining the process to make ACT more effective in supporting the patient immune response. One critical tool for developing better ACT treatments is flow cytometry. To learn more about how flow cytometry enables advances in ACTs, we spoke with Leanne Flye, associate director of scientific operations, general laboratory, at Labcorp.

Labcorp laboratories participate in company’s first-ever honey tasting competition

Beekeeping is the buzz around a number of our sites, and recently Labcorp hosted its first ever honey tasting competition.

Graphical Summary: Cancer-testis antigen burden (CTAB): A novel biomarker of tumor-associated antigens in lung cancer

Renca: A syngeneic renal cancer mouse model for testing immunotherapies

Renal cell carcinoma (RCC) primarily affects individuals aged 60 to 70 years, with men being twice as likely as women to develop the disease. Accounting for 3% of all adult cancers, RCC comprises multiple histological subtypes. Due to the asymptomatic nature of early-stage RCC, misdiagnosis and inadequate screening methods, over 50% of RCC cases are detected incidentally, and approximately 30% of patients are diagnosed with metastatic RCC. Recent advancements in the development of targeted therapies and immunotherapies to treat cancer warrant the need for an effective preclinical model with an intact and functional immune system, enabling the study of therapy-driven immune responses and tumor-induced immunosuppression.1 The Renca cell line, originating from a spontaneous renal adenocarcinoma of Balb/c mice, is a highly aggressive renal cancer cell line particularly valuable for evaluating novel immunotherapies, making it an essential tool in RCC research.2